Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth

This article has been updated

Abstract

Approximately 2% of colorectal cancer is linked to pre-existing inflammation known as colitis-associated cancer, but most develops in patients without underlying inflammatory bowel disease. Colorectal cancer often follows a genetic pathway whereby loss of the adenomatous polyposis coli (APC) tumour suppressor and activation of β-catenin are followed by mutations in K-Ras, PIK3CA and TP53, as the tumour emerges and progresses1,2. Curiously, however, ‘inflammatory signature’ genes characteristic of colitis-associated cancer are also upregulated in colorectal cancer3,4. Further, like most solid tumours, colorectal cancer exhibits immune/inflammatory infiltrates5, referred to as ‘tumour-elicited inflammation’6. Although infiltrating CD4+ TH1 cells and CD8+ cytotoxic T cells constitute a positive prognostic sign in colorectal cancer7,8, myeloid cells and T-helper interleukin (IL)-17-producing (TH17) cells promote tumorigenesis5,6, and a ‘TH17 expression signature’ in stage I/II colorectal cancer is associated with a drastic decrease in disease-free survival9. Despite its pathogenic importance, the mechanisms responsible for the appearance of tumour-elicited inflammation are poorly understood. Many epithelial cancers develop proximally to microbial communities, which are physically separated from immune cells by an epithelial barrier10. We investigated mechanisms responsible for tumour-elicited inflammation in a mouse model of colorectal tumorigenesis, which, like human colorectal cancer, exhibits upregulation of IL-23 and IL-17. Here we show that IL-23 signalling promotes tumour growth and progression, and development of a tumoural IL-17 response. IL-23 is mainly produced by tumour-associated myeloid cells that are likely to be activated by microbial products, which penetrate the tumours but not adjacent tissue. Both early and late colorectal neoplasms exhibit defective expression of several barrier proteins. We propose that barrier deterioration induced by colorectal-cancer-initiating genetic lesions results in adenoma invasion by microbial products that trigger tumour-elicited inflammation, which in turn drives tumour growth.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: IL-23 controls CRC inflammation and tumorigenesis.
Figure 2: TLR-MyD88 signalling and commensal microflora promote cytokine expression and tumorigenesis.
Figure 3: Colorectal tumours exhibit increased permeability to bacteria and their products.
Figure 4: Colorectal tumours show defective mucin production and aberrant expression of junctional proteins.

Change history

  • 07 November 2012

    The FACS image in Fig. 1e was corrected; scale bars in Figs 3b, e and f and 4a, b and f were amended.

References

  1. 1

    Vogelstein, B. & Kinzler, K. W. Cancer genes and the pathways they control. Nature Med. 10, 789–799 (2004)

    CAS  Article  Google Scholar 

  2. 2

    Fearon, E. R. & Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 61, 759–767 (1990)

    CAS  Article  Google Scholar 

  3. 3

    Wood, L. D. et al. The genomic landscapes of human breast and colorectal cancers. Science 318, 1108–1113 (2007)

    ADS  CAS  Article  Google Scholar 

  4. 4

    Reichling, T. et al. Transcriptional profiles of intestinal tumors in Apc(Min) mice are unique from those of embryonic intestine and identify novel gene targets dysregulated in human colorectal tumors. Cancer Res. 65, 166–176 (2005)

    CAS  PubMed  Google Scholar 

  5. 5

    Mantovani, A., Allavena, P., Sica, A. & Balkwill, F. Cancer-related inflammation. Nature 454, 436–444 (2008)

    ADS  CAS  Article  Google Scholar 

  6. 6

    Grivennikov, S. I., Greten, F. R. & Karin, M. Immunity, inflammation, and cancer. Cell 140, 883–899 (2010)

    CAS  Article  Google Scholar 

  7. 7

    Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331, 1565–1570 (2011)

    ADS  CAS  Article  Google Scholar 

  8. 8

    Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960–1964 (2006)

    ADS  CAS  Article  Google Scholar 

  9. 9

    Tosolini, M. et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res. 71, 1263–1271 (2011)

    CAS  Article  Google Scholar 

  10. 10

    Brenchley, J. M. & Douek, D. C. Microbial translocation across the GI tract. Annu. Rev. Immunol. 30, 149–173 (2012)

    CAS  Article  Google Scholar 

  11. 11

    McKenzie, B. S., Kastelein, R. A. & Cua, D. J. Understanding the IL-23-IL-17 immune pathway. Trends Immunol. 27, 17–23 (2006)

    CAS  Article  Google Scholar 

  12. 12

    Langowski, J. L. et al. IL-23 promotes tumour incidence and growth. Nature 442, 461–465 (2006)

    ADS  CAS  Article  Google Scholar 

  13. 13

    Hinoi, T. et al. Mouse model of colonic adenoma-carcinoma progression based on somatic Apc inactivation. Cancer Res. 67, 9721–9730 (2007)

    CAS  Article  Google Scholar 

  14. 14

    Sawa, S. et al. RORγt+ innate lymphoid cells regulate intestinal homeostasis by integrating negative signals from the symbiotic microbiota. Nature Immunol. 12, 320–326 (2011)

    ADS  CAS  Article  Google Scholar 

  15. 15

    Medzhitov, R. Recognition of microorganisms and activation of the immune response. Nature 449, 819–826 (2007)

    ADS  CAS  Article  Google Scholar 

  16. 16

    Rakoff-Nahoum, S. & Medzhitov, R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 317, 124–127 (2007)

    ADS  CAS  Article  Google Scholar 

  17. 17

    Van der Sluis, M. et al. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 131, 117–129 (2006)

    CAS  Article  Google Scholar 

  18. 18

    Velcich, A. et al. Colorectal cancer in mice genetically deficient in the mucin Muc2. Science 295, 1726–1729 (2002)

    ADS  CAS  Article  Google Scholar 

  19. 19

    Rothwell, P. M. et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377, 31–41 (2011)

    CAS  Article  Google Scholar 

  20. 20

    Wang, X., Tully, O., Ngo, B., Zitin, M. & Mullin, J. M. Epithelial tight junctional changes in colorectal cancer tissues. Sci. World J. 11, 826–841 (2011)

    CAS  Article  Google Scholar 

  21. 21

    Tanaka, T. et al. Dextran sodium sulfate strongly promotes colorectal carcinogenesis in Apc(Min/+) mice: inflammatory stimuli by dextran sodium sulfate results in development of multiple colonic neoplasms. Int. J. Cancer 118, 25–34 (2006)

    CAS  Article  Google Scholar 

  22. 22

    Meira, L. B. et al. DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. J. Clin. Invest. 118, 2516–2525 (2008)

    CAS  PubMed  PubMed Central  Google Scholar 

  23. 23

    Newman, J. V., Kosaka, T., Sheppard, B. J., Fox, J. G. & Schauer, D. B. Bacterial infection promotes colon tumorigenesis in Apc(Min/+) mice. J. Infect. Dis. 184, 227–230 (2001)

    CAS  Article  Google Scholar 

  24. 24

    Wu, S. et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nature Med. 15, 1016–1022 (2009)

    CAS  Article  Google Scholar 

  25. 25

    Dove, W. F. et al. Intestinal neoplasia in the ApcMin mouse: independence from the microbial and natural killer (beige locus) status. Cancer Res. 57, 812–814 (1997)

    CAS  PubMed  Google Scholar 

  26. 26

    Yang, L. & Pei, Z. Bacteria, inflammation, and colon cancer. World J. Gastroenterol. 12, 6741–6746 (2006)

    CAS  Article  Google Scholar 

  27. 27

    Garrett, W. S. et al. Colitis-associated colorectal cancer driven by T-bet deficiency in dendritic cells. Cancer Cell 16, 208–219 (2009)

    CAS  Article  Google Scholar 

  28. 28

    Zhou, L. et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nature Immunol. 8, 967–974 (2007)

    CAS  Article  Google Scholar 

  29. 29

    Ivanov, I. I. et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe 4, 337–349 (2008)

    CAS  Article  Google Scholar 

  30. 30

    Barker, N. et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 457, 608–611 (2009)

    ADS  CAS  Article  Google Scholar 

  31. 31

    Lennard-Jones, J. E. Classification of inflammatory bowel disease. Scand. J. Gastroenterol. Suppl. 1702–6 (1989)

  32. 32

    Bond, J. H. Polyp guideline: diagnosis, treatment, and surveillance for patients with colorectal polyps. Practice Parameters Committee of the American College of Gastroenterology. Am. J. Gastroenterol. 95, 3053–3063 (2000)

    CAS  Article  Google Scholar 

  33. 33

    Winawer, S. J. & Zauber, A. G. The advanced adenoma as the primary target of screening. Gastrointest. Endosc. Clin. N. Am. 12, 1–9 (2002)

    Article  Google Scholar 

  34. 34

    Liu, P., Jenkins, N. A. & Copeland, N. G. A highly efficient recombineering-based method for generating conditional knockout mutations. Genome Res. 13, 476–484 (2003)

    CAS  Article  Google Scholar 

  35. 35

    Ghilardi, N. et al. Compromised humoral and delayed-type hypersensitivity responses in IL-23-deficient mice. J. Immunol. 172, 2827–2833 (2004)

    CAS  Article  Google Scholar 

  36. 36

    Ye, P. et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J. Exp. Med. 194, 519–527 (2001)

    CAS  Article  Google Scholar 

  37. 37

    Awasthi, A. et al. Cutting edge: IL-23 receptor gfp reporter mice reveal distinct populations of IL-17-producing cells. J. Immunol. 182, 5904–5908 (2009)

    CAS  Article  Google Scholar 

  38. 38

    Kirkland, D. et al. B cell-intrinsic MyD88 signaling prevents the lethal dissemination of commensal bacteria during colonic damage. Immunity 36, 228–238 (2012)

    CAS  Article  Google Scholar 

  39. 39

    Kawai, T., Adachi, O., Ogawa, T., Takeda, K. & Akira, S. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 11, 115–122 (1999)

    CAS  Article  Google Scholar 

  40. 40

    Hoshino, K. et al. Cutting edge: generation of IL-18 receptor-deficient mice: evidence for IL-1 receptor-related protein as an essential IL-18 binding receptor. J. Immunol. 162, 5041–5044 (1999)

    CAS  PubMed  Google Scholar 

  41. 41

    Grivennikov, S. et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15, 103–113 (2009)

    CAS  Article  Google Scholar 

  42. 42

    Kim, P. et al. In vivo wide-area cellular imaging by side-view endomicroscopy. Nature Methods 7, 303–305 (2010)

    CAS  Article  Google Scholar 

  43. 43

    Hung, K. E. et al. Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment. Proc. Natl Acad. Sci. USA 107, 1565–1570 (2010)

    ADS  CAS  Article  Google Scholar 

  44. 44

    Chen, G. Y., Shaw, M. H., Redondo, G. & Nunez, G. The innate immune receptor Nod1 protects the intestine from inflammation-induced tumorigenesis. Cancer Res. 68, 10060–10067 (2008)

    CAS  Article  Google Scholar 

Download references

Acknowledgements

We thank eBioscience, GeneTex, Santa Cruz, BioLegend and Cell Signaling for antibodies; Genentech and Amgen for Il23−/− and Il17ra−/− mice, respectively, and S. Reid and E. Southon for the help in generating Il23rF/F mice. This work was supported by Crohn’s and Colitis Foundation of America (Career Development Award number 2693), NIH/National Institute of Diabetes and Digestive and Kidney Diseases (K99-DK088589) and a University of California, San Diego, Digestive Disease Research Development Center Pilot Grant (DK080506) to S.I.G.; Croucher Foundation and China Postdoctoral Science Foundation (20110490919) to K.W.; Strategic Young Researcher Overseas Visits Program for Accelerating Brain Circulation to K.T.; SPAR Austria to C.D.; NIH (R01CA082223) to E.R.F.; and NIH (AI043477; DK035108) and American Association for Cancer Research (07-60-21-KARI) grants to M.K., who is an American Cancer Society Research Professor. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Author information

Affiliations

Authors

Contributions

S.G. and M.K. conceived the project. S.I.G., K.W., D.M., B.S., D.J., K.T., G.Y.Y., C.O., Y.F. and K.E.H. performed the experiments. S.I.G., K.W., D.M., D.J., H.C., L.E. and M.K. analysed data. C.A.S., V.C., L.T. and G.T. generated Il23rF/F mice. M.O. and F.Y. provided Il23rgfp/gfp and Tlr2,4,9−/− bone marrow, respectively, and Y.F. and E.R.F. provided CPC-APC mice and tissues from Cdx2ERT-Cre-APC mice. C.A.S., E.R.F., H.C. and G.T. provided conceptual advice. C.D. collected and provided human specimens. S.I.G., K.W. and M.K. wrote the manuscript, with all authors contributing to the writing and providing advice.

Corresponding author

Correspondence to Michael Karin.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Information

This file contains Supplementary Table 1 and Supplementary Figures 1-11. Supplementary Figs 1e, 2b and 8a were corrected on 07 November 2012. (PDF 2192 kb)

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Grivennikov, S., Wang, K., Mucida, D. et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 491, 254–258 (2012). https://doi.org/10.1038/nature11465

Download citation

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing